Compare IZEA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | SCLX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9M | 55.1M |
| IPO Year | 2010 | N/A |
| Metric | IZEA | SCLX |
|---|---|---|
| Price | $3.34 | $6.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.3K | ★ 106.3K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,099,695.00 | N/A |
| Revenue This Year | $20.81 | $122.52 |
| Revenue Next Year | $14.86 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.32 | $4.20 |
| 52 Week High | $5.86 | $34.27 |
| Indicator | IZEA | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 41.02 |
| Support Level | N/A | $5.72 |
| Resistance Level | $3.85 | $7.77 |
| Average True Range (ATR) | 0.12 | 1.02 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 5.15 | 4.02 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.